A breakthrough therapy designation was granted to petosemtamab by the FDA to treat patients with recurrent or metastatic head and neck cancers. The Food and Drug Administration (FDA) granted a ...
Adding neoadjuvant and adjuvant pembrolizumab to the standard of care significantly improved event-free survival in patients with previously untreated, locally advanced head and neck squamous cell ...
In more recent decades, HPV has been shown as a risk factor for developing head and neck cancer. Head and neck cancer covers everything from throat, tongue, and tonsil cancer to laryngeal, mouth, and ...
Objective To evaluate the effects of neck strengthening interventions in reducing cervical neck injury and sports related concussion. Design Systematic literature review. Setting Amateur, semi ...
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain head and neck cancers from returning. Continuous use of Keytruda—both ...
CRB-701 targets Nectin-4, delivering chemotherapy directly to cancer cells, minimizing damage to healthy tissue. The FDA's fast track designation aims to expedite CRB-701's development for HNSCC and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback